ABSTRACT
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307 Immune Function and Immunosuppression in the Lung . . . . . . . . . . . . . . . . . . . . 308
Mucociliary Clearance Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309 Antimicrobial Secretions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309 Resident Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311 Pattern Recognition Receptors (PRRs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315
Immunoenhancement and Adjuvancy in the Lung . . . . . . . . . . . . . . . . . . . . . . . . . 317 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318
Disclaimer: This chapter has been reviewed by the National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, and approved for publication. Approval does not signify that the contents necessarily refl ect the views and policies of the Agency, nor does the mention of trade names or commercial products constitute endorsement or recommendation for use.
